TAK-700 in Castration Resistant Prostate Cancer

Summary

The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who failed 1st line treatment with LHRH (luteinizing hormone-releasing hormone) agonists or surgical castration.

Timeline

Start

2014-01

Primary completion

2016-01

Completion

2017-01

Drugs

Indications